Jyong Biotech (MENS) Other Accumulated Expenses (2024 - 2025)
Jyong Biotech's (MENS) quarterly Other Accumulated Expenses came in at $32000.0 in Q4 2025, down 5.88% year-on-year from $34000.0 in Q4 2024, and down 99.05% quarter-over-quarter from $3.4 million in Q2 2025.
Jyong Biotech (MENS) Other Accumulated Expenses (2024 - 2025) Analysis & Trends
Jyong Biotech's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $32000.0 for Q4 2025.
- On a quarterly basis, Other Accumulated Expenses fell 5.88% year-over-year to $32000.0 in Q4 2025; TTM through Dec 2025 was $32000.0, a 5.88% decrease from a year earlier, with the FY2025 full-year figure at $32000.0, down 5.88% from the prior year.
- Other Accumulated Expenses slipped to $32000.0 in Q4 2025 per MENS's latest filing, from $3.4 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $3.4 million in Q2 2025 and bottomed at $32000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Jyong Biotech | 177.42 Mn | 177.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32,000.00 |
| Jun 30, 2025 | 3.37 Mn |
| Dec 31, 2024 | 34,000.00 |